News-Medical.Net on MSN15h
Heart failure patients benefit from dapagliflozin after TAVR procedurePatients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback